Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib-Reference-Cited by-同舟云学术

Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib

Published:2020-09-22 Issue:10 Volume:9 Page:553-560
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Soto Elena¹,Banfield Christopher²,Gupta Pankaj²,Peterson Mark C.²

Affiliation:

1. Pfizer UK Limited Sandwich UK

2. Pfizer Inc. Cambridge Massachusetts USA

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12548

Reference21 articles.

1. Atopic Dermatitis: Global Epidemiology and Risk Factors

2. Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations

3. Janus kinases in immune cell signaling

4. Topical tofacitinib for atopic dermatitis: a phase II a randomized trial

5. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis;Gooderham M.;JAMA Dermatol.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure;Clinical Pharmacology in Drug Development;2024-08-30

2. Not just another klass (JAK) of inhibitors for allergies;Journal of Allergy and Hypersensitivity Diseases;2024-01

3. Optimal Drug Dosing to Prevent Chemotherapy Induced Neutropenia;2023-01-25

4. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors;JAMA Dermatology;2022-11-01

5. An evaluation of abrocitinib for moderate-to-severe atopic dermatitis;Expert Review of Clinical Immunology;2022-09-29